Who we are
The Critical Path to Parkinson’s Consortium (CPP) creates a collaborative environment for leading experts who come together to accelerate the path to treat those impacted by Parkinson’s. Created by C-Path, CPP fosters consensus and data-driven research among scientists from the bio-pharmaceutical industry, academic institutions, government agencies, and patient advocacy associations.
Serve as the main international vehicle to develop new, regulatory-endorsed drug development tools based on the most current scientific insights into early Parkinson’s, by combining detailed patient data, expertise in clinical trials from companies and academia, and the unique neutral facilitator role of non-profit organizations.
How we do it
CPP has collected and standardized patient-level data from PD patients around the world to develop a global integrated unified database. CPP aims to achieve global regulatory endorsement of novel translational biomarkers and drug disease trial models for use in clinical drug development trials. CPP focuses on early stages of PD, a time that offers the best chance for delaying disease progression. Early intervention is a priority need as expressed by patients.